Nicolas Tilmans
CEO
A
Anagenex
Anagenex is a biotechnology company utilizing AI-driven drug discovery to test billions of custom-synthesized compounds against disease-related protein targets, generating extensive datasets for analysis. By iteratively refining its generative AI with over 100 billion data points, Anagenex accelerates the identification of potential therapeutics, significantly reducing the time required to bring new medicines to patients.
- Artificial Intelligence
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$37.2MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Traditional drug discovery is a lengthy process, often taking over two decades to progress from identifying a disease-related protein target to delivering a medicine to patients. Existing AI approaches have been limited by the small size of available drug discovery datasets, hindering their ability to iteratively refine and accelerate the identification of potential therapeutics.
Solution
Anagenex employs an AI-driven drug discovery platform that iteratively tests billions of custom-synthesized compounds against disease-related protein targets, generating extensive, high-quality datasets. These datasets are used to train proprietary neural networks, enabling the generative AI to design new compounds with improved therapeutic potential. The platform's custom chemistry and selection systems facilitate the rapid building and testing of hundreds of millions of compounds, iteratively refining the AI's predictions and accelerating the drug discovery process. By combining large-scale data generation with advanced AI techniques, Anagenex aims to significantly reduce the time required to bring new medicines to patients.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions seeking to accelerate drug discovery and identify novel therapeutics for various diseases.
Features
- AI-driven platform for generating and screening billions of custom-synthesized compounds.
- Proprietary neural networks trained on extensive datasets to identify promising drug candidates.
- Custom chemistry and selection systems for rapid compound synthesis and testing.
- Iterative refinement of AI models based on experimental results.
- High-throughput screening capabilities for efficient evaluation of compound activity.